联合检测血清糖类抗原153糖类抗原125及癌胚抗原对乳腺癌的诊断价值

The clinical significance of combining detection of CA153 CA125 and CEA in breast cancer diagnosis

目的探讨糖类抗原(CA)153、CA125及癌胚抗原(CEA)3项肿瘤标志物联合检测对乳腺癌早期诊断和鉴别诊断的应用价值。方法采用化学发光免疫法(ECLIA)分别检测乳腺癌、乳腺良性肿瘤患者及健康体检者血清CA153、CA125及CEA的水平。结果乳腺癌患者治疗前血清CA153、CA125及CEA的水平明显高于治疗后的水平,比较差异有统计学意义(P<0.01);乳腺癌组血清CA153、CA125及CEA的水平明显高于乳腺良性疾病组和健康对照组,比较差异有统计学意义(P<0.01);另外,联合检测可以提高乳腺癌诊断的阳性率(82.8%)。结论血清CA153、CA125及CEA检测对乳腺癌的诊断具有重要临床意义,联合检测血清CA153、CA125及CEA可以提高乳腺癌的诊断率。

Objective To explore the value of three kinds tumor markers combined detection in early and differential diagnosis in breast cancer. Methods Chemoluminescence assay was used to detect serum CA153, CA125 and CEA in breast cancer, benign diseases and healthy persons. Results The levels of serum CA153, CA125 and CEA in prior treated breast cancer were significantly higher than breast cancer patients after treatment （P〈0.01）. The levels of serum CA153, CA125 and CEA in breast cancer were significantly higher than that of breast cancer group and control group （P〈0.01）. In addition,the combining detection of CA153, CA125 and CEA could improve the positive rate of diagnosis of breast cancer（82.8%）. Conclusion Detection of serum level of CA153, CA125 and CEA play an significant role in breast cancer diagnosis. The combining detection of CA153, CA125 and CEA can improve the positive rate of diagnosis of breast cancer.